Among chronic hemodialysis patients, eccentric left ventricular hypertrophy (LVH) is less responsive to treatment with angiotensin-converting enzyme (ACE) inhibitor therapy than concentric LVH, according to
Urinary continence rates are quite high and potency rates relatively high one year following laparoscopic prostatectomy. Nerve sparing surgery increases potency rates. Laurent Salomon and
By Megan Rauscher NEW YORK (Reuters Health) Oct 18 – Findings from a case-control study provide more evidence that diabetes is associated with an increased
By Roberta Friedman, PhD. SAN FRANCISCO (Reuters Health) Oct 18 – Follow-up of patients who received freeze-dried, irradiated donor fascia in two types of urogynecologic
By Ori Twersky WASHINGTON (Reuters Health) Oct 18 – Director of the US Department of Health and Human Services’ (HHS) Office for Human Research Protections
Cathy Tokarski Oct. 18, 2002 (San Diego) Although many family physicians have sought a one-year extension to comply with the electronic transaction rule under
By Susan Comninos NEW YORK (Reuters Health) Oct 14 – MacroChem Corp. said on Friday that US regulators have halted trials of the firm’s topical
NEW YORK (Reuters Health) Oct 14 – Combination therapy with gemcitabine and epirubicin appears to be a safe and effective treatment for advanced urothelial cancers
NEW YORK (Reuters Health) Oct 14 – In men with advanced prostate cancer, classifying bone scans according to the metastatic site has prognostic value, according
מדענים אמריקאים גילו כי החומר הגנטי עובר שינוי משמעותי; גוף הגבר מתקשה לסנן תאי זרע פגומים, ולכן גדלים הסיכויים להפלה או לילדים עם מומים קלים,
For patients with prostate cancer who are to undergo radical prostatectomy, 3 months of neoadjuvant hormonal therapy before surgery has no benefit and is not
The polycomb group protein ‘enhancer of zeste’ homolog 2 (EZH2) is overexpressed in hormone-refractory metastatic prostate cancer, and may be involved in cancer progression along
Leflunomide reversed chronic renal allograft dysfunction in a prospective pilot study reported in the October issue of the American Journal of Transplantation. “Leflunomide is an
The U.S. FDA has approved a supplemental new drug application for dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an
Laurie Barclay, MD Oct. 8, 2002 Most men with prostate cancer want ready access to prostate-specific antigen (PSA) screening, according to the results of
NEW YORK (Reuters Health) Oct 08 – More than 65% of African-American patients with overt type 2 diabetic nephropathy have at least one diabetic sibling
By Steven Reinberg NEW YORK (Reuters Health) Oct 08 – For patients with prostate cancer who are to undergo radical prostatectomy, 3 months of neoadjuvant
Laurie Barclay, MD Oct. 9, 2002 Editor’s Note: The Office of the Inspector General (OIG) is reining in the pharmaceutical industry with respect to
Laurie Barclay, MD Oct. 4, 2002 Ureteroscopy with holmium laser lithotripsy is a safe and effective approach to the treatment of ureteral stones during
NEW YORK (Reuters Health) Oct 04 – More than a third of peritoneal dialysis (PD) patients are not compliant with the erythropoietin (EPO) regimen they